Published in Women's Health Weekly, October 19th, 2006
According to recent research from the United States, "The discovery of predictive factors for chemoresistance is critical for improving adjuvant therapy for cancer patients. The GRP78, widely used as an indicator of the unfolded protein response (UPR), is induced in the tumor microenvironment."
"In vitro studies suggest that GRP78 confers chemoresistance to topoisomerase inhibitors, such as Adriamycin (doxorubicin)," explained E. Lee and colleagues, University of California. "Here, we report on a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.